BRIDGEWAY CAPITAL MANAGEMENT, LLC

Position in NAUT — Nautilus Biotechnology, Inc.

CIK 1107261 HOUSTON, TX

Position in NAUT

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$336,600

-$167,800 QoQ

Shares Held

180,000

+38.5% QoQ

Ownership

0.142%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#27

of 93 holders

Holding Since

Mar 2023

9 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

BRIDGEWAY CAPITAL MANAGEMENT, LLC holds $87,985,615 across 108 Biotechnology names. NAUT ranks #57 (0.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	GLUE	Monte Rosa Therapeutics, Inc.	552,566	$13,372,097
2	INVA	Innoviva, Inc.	350,253	$7,954,245
3	PBYI	Puma Biotechnology, Inc.	791,616	$6,420,005
4	RIGL	Rigel Pharmaceuticals Inc	124,184	$4,858,078
5	EXEL	Exelixis, Inc.	66,100	$3,596,501
6	CRMD	CorMedix Inc.	434,132	$3,407,936
7	KROS	Keros Therapeutics, Inc.	265,017	$2,835,681
8	PTCT	Ptc Therapeutics, Inc.	22,000	$1,794,540

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$336,600	180,000	+38.5%	Shares	Sole	2026-08-14
2026-03-31	$504,400	130,000	0.0%	Shares	Sole	2026-05-15
2025-12-31	$253,500	130,000	+4.0%	Shares	Sole	2026-02-17
2025-09-30	$105,625	125,000	0.0%	Shares	Sole	2025-11-14
2025-06-30	$90,625	125,000	+150.0%	Shares	Sole	2025-08-14
2025-03-31	$43,050	50,000	+28.9%	Shares	Sole	2025-05-15
2023-09-30	$122,608	38,800	0.0%	Shares	Sole	2023-11-14
2023-06-30	$150,156	38,800	0.0%	Shares	Sole	2023-08-14
2023-03-31	$107,476	38,800	—	Shares	Sole	2023-05-15
No filing history on record for this holder in this stock.